Ingram Micro Holding Corporation Announces Pricing of Secondary Offering of Common Stock by its Principal Stockholder.

Ingram Micro Holding Corporation Announces Pricing of Secondary Offering of Common Stock by its Principal Stockholder.

IRVINE, Calif.–(BUSINESS WIRE)–
Ingram Micro Holding Corporation (the “Company”) announced today the pricing of the previously announced secondary public offering by Ingram Holdco, LLC, an affiliate of Platinum Equity, LLC (the “Selling Stockholder”), of 12,740,384 shares of the Company’s common stock (“Common Stock,” and such offering, the “Offering”), at a price to the public of $26.00 per share, pursuant to an automatic shelf registration statement filed with the Securities and Exchange Commission (the “SEC”).

In addition, the Selling Stockholder has granted the underwriters a 30-day option to purchase up to an additional 1,730,769 shares of Common Stock at the public offering price, less underwriting discounts and commissions. The Selling Stockholder will receive all of the net proceeds from the Offering (including from the exercise of the option as described above). The Company is not offering any shares of its Common Stock in the Offering and will not receive any of the proceeds from the sale of the shares offered by the Selling Stockholder.

The Company has authorized a concurrent repurchase from the underwriters of an aggregate number of shares of the Company’s Common Stock equal to $30 million as part of the Offering at a price per share equal to the price per share at which the underwriters have agreed to purchase shares of Common Stock from the Selling Stockholder (the “Share Repurchase”). The underwriters will not receive any compensation for the Share Repurchase. The Company expects to fund the Share Repurchase with cash on hand. Although the Share Repurchase is conditioned upon, among other things, the closing of the Offering, the closing of the Offering is not conditioned upon the closing of the Share Repurchase.

Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC (collectively, the “Underwriter Representatives”) are acting as the representatives to the several underwriters and joint bookrunning managers for the Offering. BofA Securities, Deutsche Bank Securities Inc., Evercore ISI, Jefferies, RBC Capital Markets, Fifth Third Securities and Mizuho are acting as bookrunners for the proposed offering. BNP Paribas, Guggenheim Securities, Raymond James, Rothschild & Co, Stifel, William Blair and Loop Capital Markets are acting as co-managers for the proposed offering.

Subject to customary closing conditions, the Offering is expected to settle and close on or about May 7, 2026.

An automatic shelf registration statement on Form S-3 (including a prospectus) relating to these securities has been filed with the SEC and is effective. The Offering is being made solely by means of a prospectus supplement and the accompanying prospectus. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus supplement and the accompanying prospectus relating to the Offering may also be obtained by contacting: Morgan Stanley & Co. LLC, Prospectus Department, 180 Varick Street, New York, New York 10014, or email: [email protected]; Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282 (Tel: 866-471-2526) or by e-mail at [email protected]; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or email: [email protected] and [email protected].

This press release is for informational purposes only and shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of any securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About the Company

The Company (NYSE: INGM) is a leading technology company for the global information technology ecosystem. With the ability to reach more than 90% of the global population, we play a vital role in the worldwide IT sales channel, bringing products and services from technology manufacturers and cloud providers to business-to-business technology experts. Through Ingram Micro Xvantage™, our AI-powered digital platform, we offer what we believe to be the industry’s first comprehensive business-to-consumer-like experience, integrating hardware and cloud subscriptions, personalized recommendations, instant pricing, order tracking, and billing automation. We also provide various technology services, including financing, specialized marketing, lifecycle management, and technical pre- and post-sales professional support.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements may contain words such as “believes,” “expects,” “may,” “will,” “should,” “seeks,” “intends,” “plans,” “estimates,” or “anticipates,” or similar expressions, which concern our strategy, plans, projections or intentions, but such words are not the exclusive means of identifying forward-looking statements in this press release. These forward-looking statements relate to matters such as our industry, growth strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. By their nature, forward-looking statements: speak only as of the date they are made; are not statements of historical fact or guarantees of future performance; and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements should, therefore, be considered in light of various factors, including those set forth above and those included in the Company’s Annual Report on Form 10-K filed on March 3, 2026, including in the section entitled “Risk Factors,” as amended or supplemented in our subsequently filed Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Willa McManmon

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Data Management Technology Software Networks Artificial Intelligence Internet Hardware

MEDIA:

Logo
Logo

Avalo Therapeutics Announces Pricing of $375 Million Public Offering

WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced the pricing of its underwritten public offering of 19,730,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,400,000 shares of common stock. The shares of common stock are being sold at a public offering price of $17.75 per share and the pre-funded warrants are being sold at a public offering price of $17.749 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.001 per share exercise price for each pre-funded warrant. In addition, Avalo has granted the underwriters a 30-day option to purchase up to an additional 3,169,500 shares of its common stock on the same terms and conditions. The gross proceeds to Avalo from the offering are expected to be approximately $375 million, before deducting underwriting discounts and commissions and offering expenses payable by Avalo and assuming no exercise of the underwriters’ option to purchase additional shares. All of the securities being sold in the offering are being offered by Avalo. The offering is expected to close on May 7, 2026, subject to the satisfaction of customary closing conditions.

Avalo intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and short-term investments, to advance the clinical development of abdakibart, including through its Phase 3 topline data release, and for working capital and other general corporate purposes.

Leerink Partners, TD Cowen, BofA Securities, Piper Sandler and Cantor are acting as joint bookrunning managers for the offering.

The securities described above are being offered pursuant to shelf registration statement on Form S-3 (No. 333-292614) that was filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 8, 2026, and was declared effective on January 20, 2026. This offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement.

The preliminary prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC on May 5, 2026. A final prospectus supplement related to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement and an accompanying prospectus related to the offering may also be obtained, when available, from Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at [email protected]; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected]; and BofA Securities, Attention: Prospectus Department, 201 North Tryon Street, NC1-022-02-25 Charlotte, NC 28255- 0001, or by email at [email protected]; Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at [email protected]; and Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York 10022 or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody (mAb). Positive topline data was recently reported for abdakibart in a  Phase 2 clinical trial in hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, and include, but are not limited to, statements regarding the expected gross proceeds from the offering, completion and timing of the public offering and the anticipated use of proceeds from the offering. Any forward-looking statements are based on Avalo’s current expectations, forecasts, and assumptions and are subject to a number of risks and uncertainties that could cause actual outcomes and results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Avalo’s actual results to differ from those contained in the forward-looking statements in this press release, see the section entitled “Risk Factors” in Avalo’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent periodic filings with the SEC, as well as in the prospectus supplement related to the public offering. Forward-looking statements contained in this press release are based on information available to Avalo as of the date hereof and are made only as of the date of this release. Avalo undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Avalo’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Avalo.

Investor & Media Contact: 

Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
[email protected]
410-803-6793

Or

Meru Advisors
Lauren Glaser
[email protected]



Hisense Delivers 38% Sales Uplift in Western Europe Markets With NIQ’s AI-Powered Market Intelligence

Hisense Delivers 38% Sales Uplift in Western Europe Markets With NIQ’s AI-Powered Market Intelligence

NIQ insights drive international expansion and measurable growth for Hisense across key global markets

CHICAGO–(BUSINESS WIRE)–
NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new learnings from its long-standing collaboration with Hisense, a leading global brand in home appliances and smart technologies. Using NIQ’s AI‑powered market intelligence, Hisense has accelerated international expansion, improved local market decision-making, and delivered measurable growth across more than 20 key markets and 12+ categories. The case study demonstrates how AI‑driven insights help global brands move faster, localize better, and compete more effectively in complex markets.

The Challenge

As Hisense expanded internationally, it faced rising complexity across global markets. Consumer preferences differed sharply across regions such as Western Europe, Eastern Europe, and Latin America, making a one‑size‑fits‑all approach ineffective.

NIQ’s AI‑powered intelligence delivered the local market depth needed to guide investment, refine product positioning, and identify the features that mattered most in each market. By embedding NIQ insights into day‑to‑day decision‑making, Hisense shifted from retrospective reporting to faster, more proactive action–anticipating demand, aligning inventory with distributors, and adjusting pricing as market conditions evolved.

Key Results for Hisense:

  • +18% CAGR in overseas revenue including TV and household appliances (2015–2024)
  • 38% yearonyear TV value growth in Western Europe (2024)
  • Stronger competitive positioning across Europe, LATAM, and other growth regions

“For Hisense, our collaboration with NIQ is far more than access to market data—it’s the foundation for building trusted local collaborations and unlocking sustainable growth in key regions,” said Jerry Liu, Chairman, Hisense VIDAA. “NIQ doesn’t just provide numbers, they have become an extension of our team, helping us turn complexity into clarity.”

“Hisense is a strong example of how global brands can use AI‑powered market intelligence to scale with confidence,” said Julian Baldwin, President, Global Strategic Accounts at NIQ. “By combining NIQ’s proprietary data, AI-driven decision systems, and local expertise, Hisense is able to read market signals with greater speed and clarity, act on them with confidence, and turn those signals into measurable growth.”

As Hisense looks ahead, the next phase focuses on deeper AI‑driven foresight to anticipate consumer trends, support sustainability-led innovation, and enable faster, more automated decision making across the business.

This case study reflects NIQ’s broader focus on embedding AI into its core solutions, helping companies move beyond insight generation to decision systems that enable faster, smarter growth at scale.

Learn more about how AI accelerates NIQ’s The Full View™.

Frequently Asked Questions (FAQ)

What is the collaboration between NIQ and Hisense?

NIQ provides Hisense with AI‑powered market intelligence to support it’s global expansion, local market decisions, and long‑term growth. NIQ’s continuous insight ecosystem empowered Hisense to fine-tune pricing, assortment, feature sets, and inventory with speed.

How does NIQ use AI in this partnership?

NIQ uses AI to analyze large volumes of sales and consumer data, identify trends, and deliver faster, more accurate insights to support decision making. NIQ’s AI-powered foresight to anticipate consumer trends, drive smarter product innovation, and enable faster, automated decision-making across the business.

What results has Hisense achieved using NIQ insights?

Hisense delivered +18% overseas revenue CAGR, and 38% YoY TV value growth in Western Europe.

Which regions benefited most from the partnership?

Hisense has global impact across key regions including Western Europe, Eastern Europe, Latin America, and other emerging markets.

What’s next for NIQ and Hisense?

Together, NIQ and Hisense are strengthening their collaboration to unlock deeper AI-driven insights and enable smarter, more predictive decision making across the business.

About NIQ

NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing new pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modeling expertise, NIQ builds decision systems that help companies turn complex data into confident action. With operations in more than 90 countries,

NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next. For more information, please visit www.niq.com.

Forward Looking Statement:

This press release regarding the collaboration between Hisense and NIQ may contain forward-looking statements regarding anticipated consumer behaviors, market trends, and industry developments. These statements reflect current expectations and projections based on available data, historical patterns, and various assumptions. Words such as ” will”, “expects,” “anticipates,” “projects,” “believes,” “forecasts,” “plan,” “look ahead,” “indicates”, and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future outcomes and are subject to inherent uncertainties, including changes in consumer preferences, economic conditions, technological advancements, and competitive dynamics. Actual results may differ materially from those expressed or implied in these statements. While we strive to base our insights on reliable data and sound methodologies, we undertake no obligation to update any forward-looking statements to reflect future events or circumstances, except to the extent required by applicable law.

NIQ-GENERAL

© 2026 Nielsen Consumer LLC. All Rights Reserved.

Media Contact:

NIQ:[email protected]

KEYWORDS: Illinois Europe United States North America

INDUSTRY KEYWORDS: Technology Mobile/Wireless Retail Office Products Supply Chain Management Home Goods Professional Services Discount/Variety Artificial Intelligence Department Stores Supermarket Data Analytics Hardware Consumer Electronics

MEDIA:

Logo
Logo

LBL-047 Prioritized for Clinical Development in Sjögren’s Disease, Systemic Lupus Erythematosus, and Dermatomyositis

NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has selected Sjögren’s disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (known as DNTH212 outside Greater China).

Strategic Priority: Advancing Clinical Development of LBL-047

LBL-047 is a potential first- and best-in-disease bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems, this complementary and differentiated approach has the potential to address multiple autoimmune indications with improved outcomes.

As a core pipeline asset and strategic priority, Dianthus is advancing the clinical development of LBL-047 in SjD, SLE, and DM — three indications with high unmet medical need. In March 2026, Dianthus completed an upsized underwritten public offering, raising approximately $719 million in gross proceeds, providing a strong capital foundation to support the global development of LBL-047.

Phase 1 Data Anticipated in 2H’26

A two-part Phase 1 study in China in healthy volunteers (Part A) and patients with SLE (Part B) was initiated in December 2025, with top-line results in healthy volunteers expected in 2H’26. Upon completion of the Phase 1 study, Dianthus plans to provide an update on next steps for advancing its prioritized indications in clinical development.

About LBL-047

LBL-047 is a bifunctional fusion protein composed of a humanized anti-blood dendritic cell antigen 2 (BDCA2) antibody and an engineered transmembrane activator and CAML interactor (TACI) ectodomain. It is designed to selectively deplete pDCs to reduce type 1 interferon production, while simultaneously inhibiting B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) signaling pathways to suppress B-cell activation, differentiation, and antibody production. By targeting two key drivers of autoimmune disease pathogenesis, this differentiated approach has the potential to address multiple autoimmune indications. Additionally, LBL-047 has been optimized with Fc engineering to extend its half-life, offering the potential for a patient-friendly subcutaneous self-administration regimen with a dosing frequency of Q4W or less, supporting its potential as a first-line biologic therapy.

On October 16, 2025, Leads Biolabs entered into an exclusive global partnership with Dianthus, a clinical-stage biotechnology company developing next-generation therapeutics to address severe autoimmune diseases, with the total potential deal value reaching up to $1 billion. Under the agreement, Dianthus was granted exclusive global rights to research, develop, manufacture, and commercialize LBL-047 outside Greater China, where it is known as DNTH212, jointly advancing its global development to maximize clinical and commercial potential.

About Leads Biolabs

Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology, autoimmune, and other severe diseases both in China and globally.

We are a front-runner in next-generation immuno-oncology treatments with a differentiated pipeline of 14 innovative drug candidates, including four clinical-stage drug candidates and one registration-stage asset.

We adopt a science-driven R&D approach and have successfully established comprehensive R&D capabilities spanning antibody discovery and engineering, in vivo and in vitro efficacy evaluation, as well as druggability assessment. We have also developed multiple proprietary technology platforms, including LeadsBody platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform), TOPiKinectics (ADC platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical outcomes of our bispecific antibody portfolios.

We have established integrated capabilities across early discovery, translational medicine, clinical development, CMC and business development. The innovative nature and competitive strengths of our drug candidates, coupled with our global perspectives, proactive strategy, and efficient clinical validation, have made us an attractive partner for leading industry players and investment institutions. For more information, please visit https://en.leadsbiolabs.com/



Trip.com Group Limited Securities Fraud Class Action Result of Antitrust Probe and 19% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK and NEW ORLEANS, May 05, 2026 (GLOBE NEWSWIRE) —

What’s Happening:

  • Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 11, 2026 to file lead plaintiff applications in a securities class action lawsuit against Trip.com Group Limited (NasdaqGS: TCOM) (“Trip.com” or the “Company”), if they purchased or otherwise acquired the Company’s securities between April 30, 2024 and January 13, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of New York.

>>>

CLICK HERE

for more information

What You May Do:

  • If you purchased securities of Trip.com and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-tcom/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 11, 2026.

>>>To Learn More, Click

HERE

About the Lawsuit:

  • Trip.com and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On January 14, 2026, Bloomberg reported that the Company was the subject of an Antitrust Probe by the State Administration for Market Regulations of the People’s Republic of China (the ‘SAMR’) based on allegations of “abusing its market position and engaging in monopolistic practices.”   The report further stated that, “[i]n September, the market regulator in Zhengzhou summoned Trip.com for violations of rules against setting “unfair restrictions” on merchants’ transactions and prices.” On this news, the price of Trip.com ADSs fell $12.90 per ADS, or 17.05%, to close at $62.78 per ADS on January 14, 2026. The next day, it fell a further $1.48 per ADS, or 2.35%, to close at $61.30 on January 15, 2026.

The case is De Wilde v. Trip.com Group Limited, et al., Case No. 26-cv-01420.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click

HERE

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn



ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

  • Who is Involved: ImmunityBio, Inc. (NasdaqGS: IBRX) investors that purchased between January 19, 2026 and March 24, 2026
  • When to Act: Deadline to file Lead Plaintiff applications is May 26, 2026
  • Basis: ImmunityBio shares fell on FDA warning letter over cancer therapy claims in advertisement

NEW YORK and NEW ORLEANS, May 05, 2026 (GLOBE NEWSWIRE) —  Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) (“ImmunityBio” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

What You May Do

If you purchased securities of ImmunityBio and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://ksfcounsel.com/cases/nasdaqgs-ibrx-2/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 26, 2026.

>>>

CLICK HERE

for more information

About the Lawsuit

ImmunityBio and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.  

On March 24, 2026, a warning letter dated March 13, 2026, from the U.S. Food and Drug Administration to CEO Richard Adcock was made public, stating that a television advertisement and podcast misrepresented Anktiva and resulted in its distribution violating the Federal Food, Drug, and Cosmetic Act. The letter also reportedly noted that the violations “are concerning from a public health perspective because the promotional communications create a misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer.” On this news, the price of ImmunityBio’s shares fell $1.98 per share, or 21%, to close at $7.42 per share on March 24, 2026.

The case is Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261.

>>>To Learn More, Click

HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click

HERE

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner
[email protected] 
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn



SES AI Corporation Securities Fraud Class Action Result of Weak Revenue Guidance and 37% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK and NEW ORLEANS, May 05, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until June 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against SES AI Corporation (NYSE: SES) (“SES” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 29, 2025 and March 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Massachusetts.

What You May Do

If you purchased securities of SES and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-ses/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by June 26, 2026.

>>>

CLICK HERE

for more information

About the Lawsuit

SES and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.  

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company overstated its business outlook by exaggerating the potential results of agreements with companies that had limited or no operational capacity; (ii) the company created the appearance of revenue by purchasing services tied to its own Molecular Universe transactions; (iii) despite its optimistic growth statements, SES AI faced significant logistics constraints in Q4 2025 that materially impacted revenue for that quarter; (iv) these issues raised serious doubts about SES AI’s 2026 growth prospects, which were later confirmed by weaker-than-expected revenue guidance for 2026; and (v) as a result, the Company’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

The case is Patel v. SES AI Corporation, et al., Case No. 26-cv-11894.

>>>To Learn More, Click

HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click

HERE

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn



Rush Street Interactive Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders and Concurrent Repurchase of Shares

— Board of Directors Approves $100 Million Share Repurchase Program —

CHICAGO, May 05, 2026 (GLOBE NEWSWIRE) — Rush Street Interactive, Inc. (NYSE: RSI) (“RSI”), a leading online casino and sports betting company in the United States and the rest of the Americas, today announced the pricing of an underwritten secondary public offering of 10,000,000 shares of its Class A common stock by one or more trusts beneficially owned by Neil Bluhm, RSI’s Executive Chairman, Richard Schwartz, RSI’s Chief Executive Officer, and Mattias Stetz, RSI’s Chief Operating Officer (the “Selling Stockholders”), at a price to the public of $26.00 per share. The Selling Stockholders are each offering less than 10% of their respective currently owned RSI stock. The offering is expected to close on May 7, 2026, subject to the satisfaction of customary closing conditions. The underwriters will have a 30-day option to purchase up to an additional 1,500,000 shares of RSI’s Class A common stock from the Selling Stockholders.

The Selling Stockholders are offering these shares for personal financial planning and estate planning purposes. Upon completion of the offering, Neil Bluhm and trusts and other entities beneficially owned by him will continue to own over 40% of RSI’s stock, remaining RSI’s largest shareholder by a significant margin, and will continue to serve as Executive Chairman of RSI’s Board of Directors.

RSI is not offering any shares of Class A common stock in this offering and will not receive any proceeds from the sale of shares by the Selling Stockholders, but will bear the costs associated with the sale of such shares, other than any underwriting discounts and commissions.

Wells Fargo Securities and Morgan Stanley are acting as lead book-running managers and representatives of the underwriters for the offering. Jefferies, Craig-Hallum, Macquarie Capital, Needham & Company and Oppenheimer & Co. are acting as joint book-running managers for the offering. Benchmark, a StoneX Company, Citizens Capital Markets and Oakvale Capital LLP are acting as co-managers for the offering.

Concurrent Share Repurchase. Subject to the completion of the offering, RSI intends to repurchase from the underwriters 1,153,846 shares of RSI’s Class A common stock that are subject to the offering under RSI’s existing stock repurchase program at a price per share equal to the price per share to be paid by the underwriters to the Selling Stockholders in this offering. RSI intends to fund the stock repurchase with cash on hand. The repurchased shares will be cancelled and no longer outstanding following the completion of the stock repurchase. Additionally, after such repurchase, RSI’s existing stock repurchase plan will be replaced by a new $100 million stock repurchase plan approved by RSI’s Board of Directors in connection with this offering.

The offering of these securities is being made pursuant to a shelf registration statement on Form S-3 relating to these securities which has been filed with the SEC and declared effective. The offering will be made only by means of a prospectus supplement and an accompanying prospectus. A copy of the prospectus and prospectus supplement relating to the offering may be obtained, when available, by visiting the SEC’s website at www.sec.gov. Alternatively, copies of the prospectus and prospectus supplement relating to the offering may be obtained if you request it by contacting: Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, by telephone at 800-645-3751 (option #5) or by email at [email protected] or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, Telephone: 1-866-718-1649, Email: [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Rush Street Interactive

RSI is a trusted online gaming and sports entertainment company focused on markets in the United States, Canada and Latin America. Through its brands, BetRivers, PlaySugarHouse and RushBet, RSI was an early entrant in many regulated jurisdictions. It currently offers real-money mobile and online operations in fifteen U.S. states: New Jersey, Pennsylvania, Indiana, Colorado, Illinois, Iowa, Michigan, Virginia, West Virginia, Arizona, New York, Louisiana, Maryland, Ohio and Delaware, as well as in the regulated international markets of Colombia, Ontario (Canada), Mexico and Peru. RSI offers, through its proprietary online gaming platform, some of the most popular online casino games and sports betting options in the United States. Founded in 2012 by gaming industry veterans, RSI was named the 2025 EGR LatAm Awards Operator of the Year – North LatAm, the EGR North America Awards Customer Services Operator of the Year five years in a row (2020-2024), the SBC LatinoaméricaAwards 2024 Casino Operator of the Year, the 2022 EGR North America Awards Operator of the Year and Social Gaming Operator of the Year, and the 2021 Sportsbook Operator of the Year. RSI was also the first U.S.-based online casino and sports betting operator to receive RG Check iGaming Accreditation from the Responsible Gaming Council.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. RSI’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “propose”, “continue,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside RSI’s control and are difficult to predict. Important factors that could cause actual results to differ materially from those indicated in the forward-looking statements related to the offering include risks and uncertainties related to the satisfaction of customary closing conditions. Additional risks and uncertainties related to the offering, RSI and our business can be found under the heading “Risk Factors” in the documents of RSI on file with the SEC, including the risk factors discussed throughout the “Risk Factors” section of our Annual Report on Form 10-K filed on February 18, 2026 with the SEC, as such factors may be updated from time to time in periodic filings made by RSI with the SEC. RSI cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. RSI does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

Contacts

Media: 
[email protected]

Investors:
[email protected]



Gemini Space Station, Inc. Notice of May 18, 2026 Application Deadline for Class Action Lawsuit – Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS, May 05, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Gemini Space Station, Inc. (“Gemini” or the “Company”) (NasdaqGS: GEMI) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Gemini Class A common stock pursuant and/or traceable to the Company’s September 12, 2025 initial public offering (“IPO”), and/or Gemini securities between September 12, 2025 and February 17, 2026 (the “Class Period”). Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-gemi/  

Gemini investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-gemi/ to learn more.

>>>

CLICK HERE

for more information

CASE DETAILS: According to the Complaint, Gemini and certain of its executives are charged with failing to disclose material information in connection with its Offering Documents in Support of its IPO and/or during the Class Period, violating federal securities laws.

The alleged false and misleading statements and/or omissions include, but are not limited to, that: (i) the Company had overstated the viability of its core business as a crypto platform; (ii) the Company had overstated its commitment to and/or the viability of growing its business through expanding its international operations; (iii) accordingly, the Company’s post-IPO financial and business prospects were overstated; (iv) all of the foregoing raised a non-speculative risk that the Company was poised for an expensive and disruptive restructuring; and (v) as a result, the Offering Documents and defendants’ public statements throughout the class period were materially false and misleading at all relevant times.

The case is Methvin v. Gemini Space Station, Inc., et al., No. 26-cv-02261.

WHAT TO DO? If you invested in Gemini and suffered a loss during the relevant time frame, you have until May 18, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

>>>To Learn More, Click

HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click

HERE

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn



LKQ Corporation Notice of June 22, 2026 Application Deadline for Class Action Lawsuit – Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS, May 05, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in LKQ Corporation (“LKQ” or the “Company”) (NasdaqGS: LKQ) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of LKQ Corporation who were adversely affected by alleged securities fraud between February 27, 2023, and July 23, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-lkq/

LKQ investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-lkq/ to learn more.

>>>

CLICK HERE

for more information

CASE DETAILS: According to the Complaint, LKQ and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The claims against Defendants arise from misrepresentations related to the Company’s acquisition of FinishMaster, completed in August 2023, and subsequent integration.

On July 24, 2025, the Company reported second-quarter adjusted earnings that missed analyst expectations and significantly cut its full-year guidance. Among other things, the Company disclosed that its Wholesale North America segment’s margin performance continued to decline, with the Company missing EBITDA targets by approximately $20 million and suffering a year-over-year decline of 11% primarily due to increased competition from others in the industry. On this news, the price of LKQ’s shares fell by 17.8%. or $6.88 per share.

The case is City of Miami General Employees’ & Sanitation Employees’ Retirement Trust v. LKQ Corporation, No. 26-cv-00498.

WHAT TO DO? If you invested in LKQ and suffered a loss during the relevant time frame, you have until June 22, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

>>>To Learn More, Click

HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click

HERE

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn